Please login to get additional information, such as TOLEROMUNE development phases.

Not a member yet? Sign Up here, it's free!

Circassias ToleroMune technology identifies short peptide sequences, typically 10 to 20 amino acids long, from the sequence of proteins. These peptides are selected for their ability to bind promiscuously to multiple Major Histocompatibility Class II (MHC Class II) molecules on the surface of Antigen Presenting Cells. Once the peptide is bound to the MHC class II molecule it activates the T cell receptor of T lymphocytes. Circassia's ToleroMune technology selects an optimal peptide mixture to ensure broad population coverage across the multiple different MHC class II alleles. The peptides are short sequences of amino acids that can be readily synthesised and standardised. Administration of these T cell epitopes induces regulatory T cells which down regulate the allergic response to the allergens from which the peptide was originally derived. This leads to the development of tolerance to the allergen. Because the peptides selected by Circassia's ToleroMune technology are linear they do not contain the B cell epitopes which are present in whole allergen and which cause the cross-linking of IgE on the surface of mast cells. Cross-linking of IgE on the surface of mast cells is associated with itchy eyes, runny nose and, in some cases, asthmatic responses that allergic individuals suffer on exposure to allergen. Cross-linking of IgE can also cause anaphylactic type reactions.
Drug information
Highest Dev Status Phase 2
Therapeutic AreaImmunomodulation
Potential Indications Please Login
Identified Action Mechanisms1
Literature NCBI